Thomas McCauley, PhD

The chief scientific officer at Omega Therapeutics discussed how the MYCHELANGEO-1 trial may validate the company’s OEC platform.

The chief scientific officer at Omega Therapeutics discussed milestones Omega Therapeutics is looking forward to in the next year.

The chief scientific officer at Omega Therapeutics discussed the issues with other modes of therapies that OEC therapy may address.

The chief scientific officer at Omega Therapeutics discussed the importance of understanding more about and researching epigenetics.

The chief scientific officer at Omega Therapeutics discussed positive preclinical data presented at ASCO 2023.